Figure 4.
Survival analyses. Kaplan-Meier survival estimates comparing PFS of ibrutinib plus rituximab vs ibrutinib monotherapy for the whole cohort (A); patients with CXCR4 mutations (B); and patients without CXCR4 mutations (C). PFS according to CXCR4 mutational status for the whole cohort (D); patients treated with I+R (E); and patients treated with I alone (F).

Survival analyses. Kaplan-Meier survival estimates comparing PFS of ibrutinib plus rituximab vs ibrutinib monotherapy for the whole cohort (A); patients with CXCR4 mutations (B); and patients without CXCR4 mutations (C). PFS according to CXCR4 mutational status for the whole cohort (D); patients treated with I+R (E); and patients treated with I alone (F).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal